866-997-4948(US-Canada Toll Free)

Cerebral Palsy - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Feb 2017

Category :

Pharmaceutical

No. of Pages : 52 Pages

Cerebral Palsy - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cerebral Palsy Pipeline Review, H1 2017, provides an overview of the Cerebral Palsy (Central Nervous System) pipeline landscape.

Cerebral palsy is a group of disorders that can involve brain and nervous system functions, such as movement, learning, hearing, seeing, and thinking. Symptoms include muscles that are very tight and do not stretch, abnormal walk (gait), arms tucked in toward the sides, knees crossed or touching, legs make scissors movements, walk on the toes, speech problems (dysarthria), hearing or vision problems and pain. Treatment includes anticonvulsants and muscle relaxants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cerebral Palsy Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cerebral Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cerebral Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cerebral Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 7 and 1 respectively.

Cerebral Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cerebral Palsy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Cerebral Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cerebral Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cerebral Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cerebral Palsy (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cerebral Palsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cerebral Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cerebral Palsy - Overview
Cerebral Palsy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Cerebral Palsy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cerebral Palsy - Companies Involved in Therapeutics Development
Allergan Plc
Cell Cure Neurosciences Ltd
Cellular Biomedicine Group Inc
CHA Bio & Diostech Co Ltd
CytoDel LLC
GW Pharmaceuticals Plc
Medy-Tox Inc
Meridigen Biotech Co Ltd
Neuralstem Inc
Cerebral Palsy - Drug Profiles
botulinum toxin next generation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyto-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nabiximols - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NeurArrest - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSI-566 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Cerebral Palsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Cerebral Palsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Cerebral Palsy and Systemic Lupus Erythematosus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cerebral Palsy - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Cerebral Palsy, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Cerebral Palsy - Pipeline by Allergan Plc, H1 2017
Cerebral Palsy - Pipeline by Cell Cure Neurosciences Ltd, H1 2017
Cerebral Palsy - Pipeline by Cellular Biomedicine Group Inc, H1 2017
Cerebral Palsy - Pipeline by CHA Bio & Diostech Co Ltd, H1 2017
Cerebral Palsy - Pipeline by CytoDel LLC, H1 2017
Cerebral Palsy - Pipeline by GW Pharmaceuticals Plc, H1 2017
Cerebral Palsy - Pipeline by Medy-Tox Inc, H1 2017
Cerebral Palsy - Pipeline by Meridigen Biotech Co Ltd, H1 2017
Cerebral Palsy - Pipeline by Neuralstem Inc, H1 2017
Cerebral Palsy - Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Cerebral Palsy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *